Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART). Methods: Virally suppressed PLWH receiving long-term PI-containing AR...

Full description

Bibliographic Details
Main Authors:	Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	International Journal of Infectious Diseases
Subjects:	Integrase strand transfer inhibitor Nucleoside reverse transcriptase inhibitor Virological failure Resistance-associated mutation Genetic barrier
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971221001314

Similar Items

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies
by: Mounir Ait-Khaled, et al.
Published: (2021-12-01)

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
by: Sumit Arora, et al.
Published: (2023-01-01)

Role of Proviral HIV-1 DNA Genotyping for People Living with HIV (PLWH) Who Had Low-Level Viremia While Receiving Antiretroviral Therapy
by: Lv S, et al.
Published: (2023-07-01)

Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
by: Jen-Yu Hsu, et al.
Published: (2022-06-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound
by: Guan-Jhou Chen, et al.
Published: (2023-10-01)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
by: Fernandez C, et al.
Published: (2019-07-01)

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
by: Mao-Song Tsai, et al.
Published: (2023-01-01)

Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
by: Jen-Yu Hsu, et al.
Published: (2024-03-01)

How can we achieve universal access to low-cost treatment for HIV?
by: Andrew M. Hill, et al.
Published: (2016-10-01)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
by: Adetayo Emmanuel Obasa, et al.
Published: (2020-03-01)

R263K Mutation Leading to Failure of Dolutegravir-Based Treatment in a HIV Patient also Receiving Rifampicin: A Case Report
by: Jin Li, et al.
Published: (2023-05-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients
by: Dinesh Bure, et al.
Published: (2015-02-01)

Weight gain on dolutegravir: Association is not the same as causation
by: Gary Maartens, et al.
Published: (2023-05-01)

Clinical experience with dolutegravir: efficacy, safety, and tolerability
by: Isabel Furtado, et al.
Published: (2022-01-01)

Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials
by: Frank Spinelli, et al.
Published: (2021-07-01)

Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management
by: R. Chris Rathbun, et al.
Published: (2011-10-01)

Effect of Antiretroviral Therapy on Circulating Lipid Levels in Human Immunodeficiency Virus Infected Patients: A Cross-sectional Study
by: RN Devaki, et al.
Published: (2022-12-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
by: Massimiliano Fabbiani, et al.
Published: (2023-05-01)

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan
by: Yu-Tzu Tseng, et al.
Published: (2014-12-01)

Antiretroviral treatment and time since HIV-1 diagnosis are associated with large artery stiffness in sub-Saharan African HIV-1 patients
by: Titus F. Msoka, et al.
Published: (2016-10-01)

Current Treatment of HIV Infection
by: Behice KURTARAN
Published: (2015-12-01)

Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study
by: Nivriti Hurbans, et al.
Published: (2024-03-01)

HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors
by: Abid Qureshi, et al.
Published: (2018-03-01)

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
by: Maria E. Cilento, et al.
Published: (2023-09-01)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
by: Horacio Gil, et al.
Published: (2022-12-01)

A study on individualized regimen for north Indians living with human immunodeficiency virus-1 subtype C: A public health approach
by: Ashwini Yadav, et al.
Published: (2023-01-01)

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context
by: Alana T. Brennan, et al.
Published: (2023-03-01)

HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review
by: Daniel Bradshaw, et al.
Published: (2022-04-01)

Plant Coumarins with Anti-HIV Activity: Isolation and Mechanisms of Action
by: Ainur D. Sharapov, et al.
Published: (2023-02-01)

Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?
by: Athanasios-Dimitrios Bakasis, et al.
Published: (2021-05-01)

Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide
by: Ling-Ya Chen, et al.
Published: (2023-06-01)

Antiretroviral therapy-induced Leber’s hereditary optic neuropathy
by: Anand Moodley, et al.
Published: (2014-05-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
by: Lin Gan, et al.
Published: (2023-10-01)